(Q44913424)

7 December 2017

title

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases (English)

1 reference

7 December 2017

Hannes P Neeff

1

1 reference

7 December 2017

Oliver Drognitz

2

1 reference

7 December 2017

Andrea Klock

3

1 reference

7 December 2017

Gerald Illerhaus

4

1 reference

7 December 2017

Oliver G Opitz

5

1 reference

7 December 2017

Ulrich T Hopt

6

1 reference

7 December 2017

Frank Makowiec

7

1 reference

7 December 2017

publication date

6 December 2011

1 reference

International Journal of Colorectal Disease

7 December 2017

published in

1 reference

7 December 2017

volume

27

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

635-645

1 reference

https://scigraph.springernature.com/pub.10.1007/s00384-011-1360-z

7 December 2017

exact match

0 references

cites work

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Outcome after resection of hepatic and pulmonary metastases of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Expanding criteria for resectability of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Impact of complications after surgery for colorectal liver metastasis on patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Impact of steatosis on perioperative outcome following hepatic resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Sequential preoperative ipsilateral portal and arterial embolization in patients with colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Epidemiology of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1360-Z

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

12 December 2020

Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

1 reference

12 December 2020

CASH (Chemotherapy-Associated Steatohepatitis) costs

1 reference

12 December 2020

Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors

1 reference

12 December 2020

Portal and arterial embolization before extensive liver resection in patients with markedly poor functional reserve

1 reference

12 December 2020

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases

1 reference

12 December 2020

Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma.

1 reference

12 December 2020

Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases

1 reference

12 December 2020

Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome

1 reference

12 December 2020

Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.

1 reference

12 December 2020

Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy

1 reference

12 December 2020

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

1 reference

12 December 2020

10.1007/S00384-011-1360-Z

Identifiers

DOI

1 reference

7 December 2017

1 reference